Authors' reply.

Sir,

We thank Dr. P. R. Gupta[1] for his interest in our article published in Lung India (January–March 2012).[2] Although there are increasing reports on thrombocytopenia during rifampicin therapy,[3] the occurrence is mostly observed during intermittent therapy compared to daily therapy with rifampicin. The same opinion is also shared by other authors also.[45] In an article of “letter to editor” format, it is not always possible to cite each and every previously published report on the same topic due to space constraint, unlike a “review article.” More so, the technical corrections of most journals now-a-days ask for recent references to replace the older ones. Therefore, these unintentional lacunae cannot be viewed as poor search of the literature. Our article was also to stress upon the casual relationship between thrombocytopenia and rifampicin with the evidence by standardized assessment such as WHO-UMC Casualty system or Naranjo ADR Probability scale.[67] There are still fewer published reports describing these tools in their experience on thrombocytopenia during daily rifampicin therapy.[24] As well said and agreed, thrombocytopenia is a serious and life-threatening complication, and our report also illustrates the danger of noncompliance during tuberculosis treatment.